ERBB2 and breast carcinoma: Moreover, similar results to those observed for MPM have also been documented in receptor tyrosine-protein kinase erbB-2 (HER2)-positive early breast cancer, in patients with colorectal cancer and in biliary tract carcinoma, where AQP1 overexpression detected by immunohistochemistry was significantly associated with improved survival [39,40,41].